Gotham Asset Management LLC cut its position in Amgen, Inc. (NASDAQ:AMGN) by 35.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 96,059 shares of the medical research company’s stock after selling 52,844 shares during the period. Gotham Asset Management LLC’s holdings in Amgen were worth $18,700,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. Commonwealth Bank of Australia raised its holdings in Amgen by 19.7% in the 4th quarter. Commonwealth Bank of Australia now owns 66,961 shares of the medical research company’s stock valued at $13,027,000 after acquiring an additional 11,040 shares in the last quarter. UNIVEST FINANCIAL Corp raised its holdings in shares of Amgen by 1.5% during the 4th quarter. UNIVEST FINANCIAL Corp now owns 23,544 shares of the medical research company’s stock worth $4,583,000 after buying an additional 355 shares in the last quarter. Pensionfund DSM Netherlands acquired a new position in shares of Amgen during the 4th quarter worth $3,738,000. Congress Asset Management Co. MA raised its holdings in shares of Amgen by 0.8% during the 4th quarter. Congress Asset Management Co. MA now owns 40,627 shares of the medical research company’s stock worth $7,909,000 after buying an additional 311 shares in the last quarter. Finally, Duality Advisers LP acquired a new position in shares of Amgen during the 4th quarter worth $3,983,000. Institutional investors and hedge funds own 79.18% of the company’s stock.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total value of $377,760.00. Following the completion of the transaction, the director now owns 14,988 shares of the company’s stock, valued at approximately $2,830,933.44. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 6,000 shares of company stock valued at $1,144,120. Insiders own 0.27% of the company’s stock.

Shares of AMGN opened at $177.47 on Friday. Amgen, Inc. has a 12-month low of $165.22 and a 12-month high of $210.19. The company has a quick ratio of 2.57, a current ratio of 2.79 and a debt-to-equity ratio of 2.36. The stock has a market capitalization of $109.31 billion, a price-to-earnings ratio of 12.32, a PEG ratio of 2.34 and a beta of 1.21.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, January 29th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.26 by $0.16. Amgen had a return on equity of 66.74% and a net margin of 35.35%. The business had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $5.88 billion. During the same quarter in the prior year, the firm earned $2.89 EPS. As a group, research analysts forecast that Amgen, Inc. will post 13.96 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $1.45 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 dividend on an annualized basis and a yield of 3.27%. Amgen’s payout ratio is presently 40.28%.

A number of equities analysts have recently commented on the company. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. Goldman Sachs Group reissued a “buy” rating and set a $232.00 price target on shares of Amgen in a report on Thursday, January 17th. Oppenheimer set a $224.00 price target on Amgen and gave the stock a “buy” rating in a report on Sunday, January 27th. Royal Bank of Canada reissued a “neutral” rating and set a price target on shares of Amgen in a report on Monday, January 14th. Finally, Citigroup boosted their price target on Amgen from $204.00 to $210.00 and gave the stock a “neutral” rating in a report on Friday, January 4th. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $209.11.

COPYRIGHT VIOLATION NOTICE: This news story was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://theolympiareport.com/2019/04/20/gotham-asset-management-llc-sells-52844-shares-of-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: Limitations of the P/E Growth ratio

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.